Media headlines about Evolent Health (NYSE:EVH) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Evolent Health earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 45.1731871286889 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Earnings Growth Make Evolent Health (EVH) a Sell – Investorplace.com (investorplace.com)
- Bloomberg Markets: Dave Wilson’s Chart of the Day for Nov. 6 (bloomberg.com)
- Brokerages Expect Evolent Health, Inc (EVH) to Post -$0.05 EPS (americanbankingnews.com)
- Relative Strength Alert For Evolent Health (thestreet.com)
Shares of Evolent Health (NYSE EVH) traded down $0.55 on Friday, reaching $11.15. 3,966,800 shares of the company’s stock were exchanged, compared to its average volume of 1,214,106. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.89 and a current ratio of 1.89. Evolent Health has a 1 year low of $10.35 and a 1 year high of $27.50.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.27%. The firm had revenue of $107.90 million for the quarter, compared to analyst estimates of $104.49 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The business’s revenue was up 79.2% on a year-over-year basis. analysts anticipate that Evolent Health will post -0.57 earnings per share for the current year.
A number of brokerages recently issued reports on EVH. BidaskClub cut shares of Evolent Health from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. ValuEngine cut shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Robert W. Baird set a $35.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a report on Tuesday, August 8th. Zacks Investment Research cut shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Cowen and Company restated an “outperform” rating and set a $29.00 price objective (down previously from $33.00) on shares of Evolent Health in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $28.70.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.